COPENHAGEN, Feb 26 (Reuters) - Drug maker Novo Nordisk (NOVOb.CO: Quote, Profile , Research) said on Monday it had decided not to seek regulatory approval for its drug NovoSeven to treat bleeding in the brain, sending its shares down almost 8 percent. The Danish firm said initial results from a phase III clinical trial showed that its anti-bleeding drug NovoSeven reduces bleeding in the brain, but does not improve long-term clinical outcomes.
